{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"066-485-719-033-261","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"066-485-719-033-261","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8909,"type":"PATENT","title":"Cornell Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11969,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8223,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
selecting a cancer patient having an increased blood or tissue level of vascular endothelial growth factor receptor 1+ (VEGFR1+) bone marrow derived progenitor cells compared to a prior measured level of VEGFR1+ bone marrow derived progenitor cells in the patient and\n
administering to the selected cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells selected from the group consisting of a VEGFR1 inhibitor, a VLA-4 inhibitor, and an MMP-9 inhibitor under conditions effective to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein said administering is carried out at a time period corresponding to when vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 2, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by chemotherapy, stress, surgery, inflammation, irradiation, or growth factors."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by chemotherapy."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by stress."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by surgery."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by mobilization of inflammatory cells."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by irradiation."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by growth factors."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 9, wherein the growth factors are selected from the group consisting of granulocyte colony stimulating factors, granulocyte macrophage stimulating factors, and growth hormones that stimulate bone marrow cell growth."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells binds to vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells prevents or reduces formation of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells is a vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell-specific antibody or antigen-binding portion thereof."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 13, wherein a polyclonal antibody is administered."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 13, wherein a monoclonal antibody is administered."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 13, wherein an antigen-binding portion of an antibody is administered."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the inhibitor is an antibody or antigen-binding portion of an antibody capable of binding to VLA-4 (α4β1) integrin."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein said administering is part of an adjuvant therapy regime."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A method of preventing metastases in a cancer patient, said method comprising:\n
selecting a cancer patient having an increased blood or tissue level of vascular endothelial growth factor receptor 1+ (VEGFR1+) bone marrow derived progenitor cells compared to a prior measured level of VEGFR1+ bone marrow derived progenitor cells in the patient and\n
administering to the selected cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells selected from the group consisting of a VEGFR1 inhibitor, a VLA-4 inhibitor, and an MMP-9 inhibitor under conditions effective to prevent metastases in the cancer patient."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein said administering is carried out at a time period corresponding to when vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 20, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by chemotherapy, stress, surgery, inflammation, irradiation, or growth factors."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by chemotherapy."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by stress."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by surgery."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by mobilization of inflammatory cells."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by irradiation."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 21, wherein vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell mobilization is stimulated by growth factors."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 27, wherein the growth factors are selected from the group consisting of granulocyte colony stimulating factors, granulocyte macrophage stimulating factors, and growth hormones that stimulate bone marrow cell growth."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells binds to vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells prevents or reduces formation of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein the inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cells is a vascular endothelial growth factor receptor 1+ bone marrow-derived progenitor cell-specific antibody or antigen-binding portion thereof."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 31, wherein a polyclonal antibody is administered."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 31, wherein a monoclonal antibody is administered."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 31, wherein an antigen-binding portion of an antibody is administered."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein the inhibitor is an antibody or an antigen-binding portion of an antibody capable of binding to VLA-4 (α4β1) integrin."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein said administering is part of an adjuvant therapy regime."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["A method of preventing or inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation, said method comprising:\n
selecting a cancer patient having had a primary tumor resection and having an increased blood or tissue level of vascular endothelial growth factor receptor 1+ (VEGFR1+) bone marrow derived progenitor cells compared to a prior measured level of VEGFR1+ bone marrow derived progenitor cells in the patient and\n
administering to the selected cancer patient a VEGFR1 inhibitor, a VLA-4 inhibitor, or an MMP-9 inhibitor under conditions effective to prevent or inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 37, wherein the inhibitor is an antibody or an antigen-binding portion of an antibody capable of binding to VEGFR1."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the inhibitor is an antibody or an antigen-binding portion of an antibody capable of binding to VEGFR1."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19, wherein the inhibitor is an antibody or an antigen-binding portion of an antibody capable of binding to VEGFR1."],"number":40,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}